156 related articles for article (PubMed ID: 11780146)
21. Domain swapping in N-truncated human cystatin C.
Janowski R; Abrahamson M; Grubb A; Jaskolski M
J Mol Biol; 2004 Jul; 341(1):151-60. PubMed ID: 15312769
[TBL] [Abstract][Full Text] [Related]
22. Higher-order interactions of Bcr-Abl can broaden chronic myeloid leukemia (CML) drug repertoire.
Liu Y; Zhang M; Jang H; Nussinov R
Protein Sci; 2023 Jan; 32(1):e4504. PubMed ID: 36369657
[TBL] [Abstract][Full Text] [Related]
23. Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.
Underhill-Day N; Pierce A; Thompson SE; Xenaki D; Whetton AD; Owen-Lynch PJ
Br J Haematol; 2006 Mar; 132(6):774-83. PubMed ID: 16487179
[TBL] [Abstract][Full Text] [Related]
24. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
Ren SY; Xue F; Feng J; Skorski T
Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
[TBL] [Abstract][Full Text] [Related]
25. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
[TBL] [Abstract][Full Text] [Related]
26. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions.
Chantalat L; Skoufias DA; Kleman JP; Jung B; Dideberg O; Margolis RL
Mol Cell; 2000 Jul; 6(1):183-9. PubMed ID: 10949039
[TBL] [Abstract][Full Text] [Related]
27. Molecular mechanisms of transformation by the BCR-ABL oncogene.
Sattler M; Griffin JD
Semin Hematol; 2003 Apr; 40(2 Suppl 2):4-10. PubMed ID: 12783368
[TBL] [Abstract][Full Text] [Related]
28. Interaction of Bcr/Abl with C3G, an exchange factor for the small GTPase Rap1, through the adapter protein Crkl.
Cho YJ; Hemmeryckx B; Groffen J; Heisterkamp N
Biochem Biophys Res Commun; 2005 Aug; 333(4):1276-83. PubMed ID: 15982636
[TBL] [Abstract][Full Text] [Related]
29. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein.
McWhirter JR; Wang JY
Oncogene; 1997 Oct; 15(14):1625-34. PubMed ID: 9349495
[TBL] [Abstract][Full Text] [Related]
30. The N-terminal coiled coil of the Rhodococcus erythropolis ARC AAA ATPase is neither necessary for oligomerization nor nucleotide hydrolysis.
Zhang X; Stoffels K; Wurzbacher S; Schoofs G; Pfeifer G; Banerjee T; Parret AH; Baumeister W; De Mot R; Zwickl P
J Struct Biol; 2004; 146(1-2):155-65. PubMed ID: 15037247
[TBL] [Abstract][Full Text] [Related]
31. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice.
Heisterkamp N; Voncken JW; Senadheera D; Hemmeryckx B; Gonzalez-Gomez I; Reichert A; Pattengale PK; Groffen J
Int J Mol Med; 2001 Apr; 7(4):351-7. PubMed ID: 11254872
[TBL] [Abstract][Full Text] [Related]
32. Solution structure of a C-terminal coiled-coil domain from bovine IF(1): the inhibitor protein of F(1) ATPase.
Gordon-Smith DJ; Carbajo RJ; Yang JC; Videler H; Runswick MJ; Walker JE; Neuhaus D
J Mol Biol; 2001 Apr; 308(2):325-39. PubMed ID: 11327770
[TBL] [Abstract][Full Text] [Related]
33. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.
Dixon AS; Miller GD; Bruno BJ; Constance JE; Woessner DW; Fidler TP; Robertson JC; Cheatham TE; Lim CS
Mol Pharm; 2012 Jan; 9(1):187-95. PubMed ID: 22136227
[TBL] [Abstract][Full Text] [Related]
34. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping.
Janowski R; Kozak M; Jankowska E; Grzonka Z; Grubb A; Abrahamson M; Jaskolski M
Nat Struct Biol; 2001 Apr; 8(4):316-20. PubMed ID: 11276250
[TBL] [Abstract][Full Text] [Related]
35. Disruption of Bcr-Abl coiled coil oligomerization by design.
Dixon AS; Pendley SS; Bruno BJ; Woessner DW; Shimpi AA; Cheatham TE; Lim CS
J Biol Chem; 2011 Aug; 286(31):27751-60. PubMed ID: 21659527
[TBL] [Abstract][Full Text] [Related]
36. Crystal structure of a truncated mutant of glucose-fructose oxidoreductase shows that an N-terminal arm controls tetramer formation.
Lott JS; Halbig D; Baker HM; Hardman MJ; Sprenger GA; Baker EN
J Mol Biol; 2000 Dec; 304(4):575-84. PubMed ID: 11099381
[TBL] [Abstract][Full Text] [Related]
37. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
McWhirter JR; Galasso DL; Wang JY
Mol Cell Biol; 1993 Dec; 13(12):7587-95. PubMed ID: 8246975
[TBL] [Abstract][Full Text] [Related]
38. Structure of the EMMPRIN N-terminal domain 1: dimerization via beta-strand swapping.
Luo J; Teplyakov A; Obmolova G; Malia T; Wu SJ; Beil E; Baker A; Swencki-Underwood B; Zhao Y; Sprenkle J; Dixon K; Sweet R; Gilliland GL
Proteins; 2009 Dec; 77(4):1009-14. PubMed ID: 19768682
[No Abstract] [Full Text] [Related]
39. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.
Hantschel O; Grebien F; Superti-Furga G
Cancer Res; 2012 Oct; 72(19):4890-5. PubMed ID: 23002203
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of thiadiazoles and thiazoles targeting the Bcr-Abl T315I mutant: from docking false positives to ATP-noncompetitive inhibitors.
Radi M; Crespan E; Falchi F; Bernardo V; Zanoli S; Manetti F; Schenone S; Maga G; Botta M
ChemMedChem; 2010 Aug; 5(8):1226-31. PubMed ID: 20509136
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
